Structure-activity relationship of macrocyclic and linear gadolinium chelates: Investigation of transmetallation effect on the zinc-dependent metallopeptidase angiotensin-converting enzyme

Journal of Magnetic Resonance Imaging

Volumn 8, Issue 3, 1998, Pages 695-702

  Corot, Claire ^a,b   Idee, Jean Marc ^a   Hentsch, Anne Marie ^a   Santus, Robin ^a   Mallet, Catherine ^a   Goulas, Valérie ^a   Bonnemain, Bruno ^a   Meyer, Dominique ^a  

^a Laboratoire Guerbet   (France)

^b Biomatech   (France)

Author keywords

Angiotensin converting enzyme; Gd chelates; MRI contrast agents; Zn

Indexed keywords

CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; METALLOPROTEINASE;

ARTICLE; BIOCOMPATIBILITY; CONTRAST ENHANCEMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

CHELATING AGENTS; CHEMISTRY; CONTRAST MEDIA; GADOLINIUM; GADOLINIUM DTPA; HETEROCYCLIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; ORGANOMETALLIC COMPOUNDS; PEPTIDYL-DIPEPTIDASE A; STRUCTURE-ACTIVITY RELATIONSHIP; ZINC;

EID: 0031834816     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.1880080328     Document Type: Article

References (29)

1. Handcock RD, Martell AE. Ligand design for selective complexation of metal ions in aqueous solution. Chem Rev 1989; 89: 1875-1914.
2. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev 1987; 87:901-927.
3. May P, Bulman R. The present status of chelating agents in medicine. In: Ellis GP, West GB, eds. Progress in medicinal chemistry, 1983. Vol. 20. New York: Elsevier Science Publishers, 1983; 225.
4. Runge VM, Gelblum DY. Future directions in magnetic resonance contrast media. Top Magn Reson Imaging 1991; 3:85-97.
5. n in mice. Nucl Med Biol 1988; 15:395-402.
6. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990; 8:467-481.
7. Tweedle MF. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 1992; 27:S2-S6.
8. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radio-labeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995; 30:372-380.
9. Puttagunta NR, Gibbly WA, Smith GT. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Invest Radiol 1996; 31:739-742.
10. Puttagunta NR, Gibby WA, Puttagunta VL. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis glucosamide and other magnetic resonance imaging contrast media. Invest Radiol 1996; 10:619-624.
11. Bunning P, Riordan JF. The functional role of zinc in angiotensin-converting enzyme: implications for the enzyme mechanism. J Inorg Chem 1985; 24:183-198.
12. Ondetti MA, Cushman DW. Enzymes of the renin-angiotensin system and their inhibitors. Annu Rev Biochem 1982; 51:283-308.
13. Hooper NM. Angiotensin-converting enzyme: implications from molecular biology for its physiological functions. Int J Biochem 1991; 23:641-647.
14. Ondetti MA, Cushman DW. Angiotensin-converting enzyme inhibitors: biochemical properties and biological actions. CRC Crit Rev Biochem 1984; 16:381-411.
15. Corot C, Hentsch AM, Curtelin L. Interaction of gadolinium complexes with metal-dependent biological systems. Invest Radiol 1994; 29(suppl):S164-S167.
16. Idée JM, Berthommier C, Goulas V, et al. Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation. Biometals 1998; 11:113-123.
17. Tweedle MF, Hagan JJ, Kumar K, et al. Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging 1991; 9:409-415.
18. Chang CA. Magnetic resonance imaging contrast agents. Design and physicochemical properties of gadodiamide. Invest Radiol 1993; 28(suppl 1):S21-S27.
19. Holmquist B, Bunning P, Riordan JF. A continuous spectrophotometric assay for angiotensin-converting enzyme. Ann Biochem 1979; 95:540-548.
20. Voet D, Voet JD. Rate of enzymatic reactions. In: Voet D, ed. Biochemistry 1990. New York: John Wiley & Sons, 1990; 329-333.
21. Reeves PG, O'Dell BL. Effects of dietary zinc deprivation on the activity of angiotensin-converting enzyme in serum of rats and guinea pigs. J Nutr 1986; 116:128-134.
22. Dahlheim H, White CL, Rothemund J, Von Lutterotti N, Jacob IC, Rosenthal I. Effect of zinc depletion on angiotensin I converting enzyme in arterial walls and plasma of the rat. Miner Electrolyte Metab 1989; 15:125-129.
23. Harpur ES, Worah D, Hals PA, et al. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 1993; 28(suppl):S28-S43.
24. Kundu GC, Wilson IB. Endothelin-converting enzyme: the binding of metal ions. Int J Peptide Protein Res 1993; 42:64-67.
25. Roques BP, Noble F, Dauge FV, et al. Neutral endopeptidase 24.11. Structure, inhibition, experimental and clinical pharmacology. Pharmacol Rev 1993; 45:87-147.
26. Niendorf H. Serum iron and serum bilirubin after administration of Gd-DTPA-dimeglumine. A pharmacologic study in healthy volunteers. Invest Radiol 1988; 23(suppl 1):S275-S280.
27. Niendorf H. Tolerance data of Gd-DTPA: a review. Eur J Radiol 1991; 13:15-20.
28. Hattner R, White D. Gallium/stable gadolinium antagonism: MRI contrast agent markedly alters the normal biodistribution of gallium-67. J Nucl Med 1990; 31:1844-1846.
29. Jackson GE, Byrne MJ. Metal ion speciation in blood plasma: gallium-67-citrate and MRI contrast agents. J Nucl Med 1996; 37:379-386.